Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 9, 2026
- Heron Therapeutics and CorMedix Therapeutics entered a definitive agreement for CorMedix to acquire substantially all of its assets, subject to stockholder approval and customary closing conditions. Q3 2026 net revenue was $35.3 million, versus $38.2 million in Q3 2025.
- 10-Q report · filed Nov 9, 2026
- Heron Therapeutics agreed to sell substantially all assets to CorMedix for 14,583,333 shares and $145.0 million cash, plus royalties and earn-outs, with closing expected in the first quarter of 2027.
The audio replay and transcript follow the call.